Developer docs
API playgroundTry for free, no card

Search company profiles

NeuSpera Medical

Full company profile

uuid0000dn8

Namestring
NeuSpera Medical
Legal namestring
Neuspera Medical, Inc.
Websiteurl
neuspera.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

NeuSpera Medical, Inc. is a San Jose, California-based medical device company founded in 2014 (originally as Vivonda Medical) that designs, manufactures, and commercializes ultra-miniaturized implantable neuromodulation systems. Its core innovation is a proprietary Mid-Field Powering Technology that uses evanescent and propagating electromagnetic waves to wirelessly power and communicate with devices implanted up to 10cm deep in the body, enabling implants that are more than 100x smaller than traditional battery-powered neuromodulation devices. This architecture eliminates implanted batteries and the associated surgical complications while delivering efficacy comparable to traditional sacral neuromodulation (SNM).

The company's flagship product is the FDA-approved Integrated Sacral Neuromodulation (iSNM) System for urinary urge incontinence (UUI), approved in June 2025. The system consists of an ultra-miniaturized neurostimulator implanted near the sacral nerve, an external battery/therapy disc worn against the lower back, and a companion smartphone app for patient therapy adjustments, with an iPad-based clinician programmer for physician data access. NeuSpera also markets an FDA-cleared Peripheral Nerve Stimulation (PNS) System for chronic peripheral nerve pain, cleared in April 2023. The company serves adult patients (predominantly women) with UUI/OAB and the urologists and urogynecologists who implant the devices, targeting a market of approximately 300 million affected patients worldwide.

NeuSpera generates revenue through hardware sales of its implantable devices and recurring external battery/accessory components, distributed via direct physician engagement at hospital systems and specialty urology practices. The company is in the earliest stages of commercial launch following June 2025 FDA approval, and is building out its commercial organization under Chief Commercial Officer Steve Paul, with a leadership team recruited from Boston Scientific, Abbott, Coloplast, Ivantis, and Vertos Medical. The company has raised approximately $122 million in equity financing across angel, Series A through Series D rounds, with Vertex Ventures HC and Treo Ventures as repeated lead investors.

Short descriptiontext

NeuSpera Medical is a San Jose-based medical device company that has developed ultra-miniaturized, battery-free implantable neuromodulation systems powered by its proprietary Mid-Field Powering Technology. Its FDA-approved iSNM system treats urinary urge incontinence, serving predominantly female adult patients and the urologists/urogynecologists who implant the device.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Jose, United States
HQ citystring
San Jose
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
implantable neuromodulation devices, sacral neuromodulation therapy, peripheral nerve stimulation, wireless medical implants, urinary incontinence treatment
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Implantable Neuromodulation Medical Devices
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Implantable Medical Device Sales
TypeHardware Sales
Description

Neuspera generates revenue from the sale of its implantable neurostimulation devices, including the FDA-approved iSNM system for urinary urge incontinence and the FDA-cleared peripheral nerve stimulation system. The company sells through direct engagement with healthcare providers and is building its commercial organization for full market launch.

neuspera.com
2External Therapy Disc / Wearable Component Sales
TypeHardware Sales
Description

The company sells external battery discs and accessories that work in conjunction with the implanted neurostimulator. These external components represent recurring consumable/accessory revenue for patients using the iSNM system.

neuspera.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Nuvella
Description

First-generation sacral neuromodulation system name used during clinical trials; later branded as iSNM system

neuspera.com
+2 more records
Core offering1 text field

NeuSpera Medical designs, manufactures, and sells ultra-miniaturized implantable neuromodulation medical devices powered by its proprietary Mid-Field Powering Technology. The company's flagship product is the FDA-approved Integrated Sacral Neuromodulation (iSNM) system for urinary urge incontinence, which consists of an ultra-miniaturized implant, an external battery disc, a smartphone app, and an iPad-based clinician programmer. The company also offers an FDA-cleared Peripheral Nerve Stimulation (PNS) system for chronic nerve pain, and external wearable components that represent recurring accessory revenue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 84.2% of implanted patients achieved at least 50% reduction in urgent leaks at 6 months (Phase II pivotal trial, 128 patients)
+9 more records
Product overview1 text field

Neuspera Medical offers a portfolio of ultra-miniaturized neuromodulation devices powered by proprietary Mid-Field Powering Technology. The flagship product is the FDA-approved Integrated Sacral Neuromodulation (iSNM) System (also known as Nuvella during clinical trials) for treating urinary urge incontinence, which includes an implantable neurostimulator, external therapy disc, and companion smartphone application. The company also markets an FDA-cleared Peripheral Nerve Stimulation System for chronic pain. All products leverage wireless powering to eliminate the need for implanted batteries, significantly reducing device size and improving patient comfort compared to traditional neuromodulation systems.

Product and service2 records
1Neuspera Integrated Sacral Neuromodulation (iSNM) System
CategoryImplantable Sacral Neuromodulation System
Description

FDA-approved integrated sacral neuromodulation system for urinary urge incontinence (UUI) consisting of an ultra-miniaturized neurostimulator implant (100x smaller than traditional devices), an external battery/therapy disc worn against the lower back, a smartphone application for therapy adjustments, and an iPad-based clinician programmer. Eliminates the need for implanted batteries while delivering gold-standard SNM efficacy. Designed for urologists and urogynecologists treating UUI patients who have failed medication management.

2Neuspera Peripheral Nerve Stimulation (PNS) System
CategoryImplantable Peripheral Nerve Stimulation System
Description

FDA-cleared first-of-its-kind leadless micro-implant system for chronic peripheral nerve pain management. 75x smaller than the smallest commercial implantable pulse generator, featuring a wireless platform with wearable transmitter and iPad-based clinician programmer. Designed for pain management physicians and specialists treating chronic peripheral nerve pain.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-06-03
Description

Neuspera was selected as one of 65 startups in the 2024 MedTech Innovator Cohort, providing visibility within the medtech ecosystem and access to mentorship, networking, and potential partnership opportunities with larger medtech companies.

Strategic tierMinorTypeOthers
Description

Neuspera Medical is a member of AdvaMed (Advanced Medical Technology Association), the leading trade association for the medical technology industry. The company and its employees follow applicable laws and regulations for the medical device industry.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medtronic is the incumbent market leader in sacral neuromodulation through its InterStim system, which has dominated the UUI/OAB market since 1997. Medtronic is Neuspera's primary direct competitor and the entrenched incumbent Neuspera must displace, with deep physician relationships and a multi-decade head start in SNM.

TypeDirect peer
Description

Axonics is Neuspera's most direct competitor, offering rechargeable sacral neuromodulation and peripheral nerve stimulation systems. Axonics was acquired by Boston Scientific, giving it the resources and salesforce to compete aggressively against Neuspera's battery-free iSNM system.

TypeBroad incumbent
Description

Boston Scientific is a broad incumbent in neuromodulation (spinal cord stimulation, deep brain stimulation, dorsal root ganglion) and acquired Axonics in 2024 to enter the SNM market. Courtney Lane, Neuspera's VP of Clinical, Quality and Regulatory, previously led clinical affairs at Axonics and worked on Boston Scientific's DBS program.

4Abbott
TypeBroad incumbent
Description

Abbott is a broad neuromodulation incumbent with the Proclaim DRG system for dorsal root ganglion stimulation and other neurostimulation products. As a large diversified medical device company with extensive salesforce coverage, Abbott represents both a competitive threat and potential strategic acquirer for smaller neuromodulation players.

TypeEmerging player
Description

Inspire Medical Systems is an emerging neuromodulation company with an FDA-approved hypoglossal nerve stimulation system for obstructive sleep apnea. Inspire represents a successful case study of a focused neuromodulation company scaling to commercial success, with a comparable sales motion to urology/specialty physician segments.

TypeDirect peer
Description

Nevro develops the Senza spinal cord stimulation system for chronic pain, competing in the neuromodulation space with Neuspera's PNS system. Both companies target the chronic pain market with neurostimulation devices, though Nevro focuses on spinal cord while Neuspera targets peripheral nerves.

TypeEmerging player
Description

Saluda Medical is an emerging neuromodulation company with the Evoke spinal cord stimulation system featuring closed-loop sensing technology. Saluda represents a next-generation neuromodulation competitor with innovative technology approaches similar to Neuspera's proprietary mid-field powering platform.

TypeEmerging player
Description

SPR Therapeutics develops peripheral nerve stimulation systems for pain management, directly competing with Neuspera's FDA-cleared PNS system. SPR focuses on minimally-invasive PNS for acute and chronic pain, representing an emerging competitor in Neuspera's PNS indication.

TypeEmerging player
Description

Nalu Medical develops a miniature peripheral nerve stimulation system for chronic pain, competing with Neuspera's PNS platform. Nalu's ultra-small implant and wearable battery form factor parallels Neuspera's miniaturization approach, making it a comparable emerging player in PNS.

TypeBroad incumbent
Description

Coloplast is a major urology medical device company offering continence care products and interventional urology solutions. Neuspera's former CEO Steffen Hovard previously led Coloplast Interventional Urology, and Coloplast competes broadly in the urology space where Neuspera is launching its iSNM system.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeuSpera Medical

Implantable Neuromodulation Medical Devicesneuspera.com

NeuSpera Medical is a San Jose-based medical device company that has developed ultra-miniaturized, battery-free implantable neuromodulation systems powered by its proprietary Mid-Field Powering Technology. Its FDA-approved iSNM system treats urinary urge incontinence, serving predominantly female adult patients and the urologists/urogynecologists who implant the device.

What NeuSpera Medical does

NeuSpera Medical, Inc. is a San Jose, California-based medical device company founded in 2014 (originally as Vivonda Medical) that designs, manufactures, and commercializes ultra-miniaturized implantable neuromodulation systems. Its core innovation is a proprietary Mid-Field Powering Technology that uses evanescent and propagating electromagnetic waves to wirelessly power and communicate with devices implanted up to 10cm deep in the body, enabling implants that are more than 100x smaller than traditional battery-powered neuromodulation devices. This architecture eliminates implanted batteries and the associated surgical complications while delivering efficacy comparable to traditional sacral neuromodulation (SNM).

The company's flagship product is the FDA-approved Integrated Sacral Neuromodulation (iSNM) System for urinary urge incontinence (UUI), approved in June 2025. The system consists of an ultra-miniaturized neurostimulator implanted near the sacral nerve, an external battery/therapy disc worn against the lower back, and a companion smartphone app for patient therapy adjustments, with an iPad-based clinician programmer for physician data access. NeuSpera also markets an FDA-cleared Peripheral Nerve Stimulation (PNS) System for chronic peripheral nerve pain, cleared in April 2023. The company serves adult patients (predominantly women) with UUI/OAB and the urologists and urogynecologists who implant the devices, targeting a market of approximately 300 million affected patients worldwide.

NeuSpera generates revenue through hardware sales of its implantable devices and recurring external battery/accessory components, distributed via direct physician engagement at hospital systems and specialty urology practices. The company is in the earliest stages of commercial launch following June 2025 FDA approval, and is building out its commercial organization under Chief Commercial Officer Steve Paul, with a leadership team recruited from Boston Scientific, Abbott, Coloplast, Ivantis, and Vertos Medical. The company has raised approximately $122 million in equity financing across angel, Series A through Series D rounds, with Vertex Ventures HC and Treo Ventures as repeated lead investors.

NeuSpera Medical firmographics

Firmographics
Name
NeuSpera Medical
Legal name
Neuspera Medical, Inc.
Website
https://neuspera.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
NeuSpera Medical is a San Jose-based medical device company that has developed ultra-miniaturized, battery-free implantable neuromodulation systems powered by its proprietary Mid-Field Powering Technology. Its FDA-approved iSNM system treats urinary urge incontinence, serving predominantly female adult patients and the urologists/urogynecologists who implant the device.
Ownership category
akta.pro rank

NeuSpera Medical industry classification

Industry
Product category
Implantable Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)

Keywords

  • Implantable neuromodulation devices
  • Sacral neuromodulation therapy
  • Peripheral nerve stimulation
  • Wireless medical implants
  • Urinary incontinence treatment

Where NeuSpera Medical is headquartered

Location

Headquarters

HQ city
San Jose
HQ country
United States
HQ region
North America

Offices1 record

Markets served

NeuSpera Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales

Revenue model

  1. Implantable Medical Device Sales: Neuspera generates revenue from the sale of its implantable neurostimulation devices, including the FDA-approved iSNM system for urinary urge incontinence and the FDA-cleared peripheral nerve stimulation system. The company sells through direct engagement with healthcare providers and is building its commercial organization for full market launch.
  2. External Therapy Disc / Wearable Component Sales: The company sells external battery discs and accessories that work in conjunction with the implanted neurostimulator. These external components represent recurring consumable/accessory revenue for patients using the iSNM system.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels6 records

NeuSpera Medical product offering

Product offering

Core offering

NeuSpera Medical designs, manufactures, and sells ultra-miniaturized implantable neuromodulation medical devices powered by its proprietary Mid-Field Powering Technology. The company's flagship product is the FDA-approved Integrated Sacral Neuromodulation (iSNM) system for urinary urge incontinence, which consists of an ultra-miniaturized implant, an external battery disc, a smartphone app, and an iPad-based clinician programmer. The company also offers an FDA-cleared Peripheral Nerve Stimulation (PNS) system for chronic nerve pain, and external wearable components that represent recurring accessory revenue.

Product overview

Neuspera Medical offers a portfolio of ultra-miniaturized neuromodulation devices powered by proprietary Mid-Field Powering Technology. The flagship product is the FDA-approved Integrated Sacral Neuromodulation (iSNM) System (also known as Nuvella during clinical trials) for treating urinary urge incontinence, which includes an implantable neurostimulator, external therapy disc, and companion smartphone application. The company also markets an FDA-cleared Peripheral Nerve Stimulation System for chronic pain. All products leverage wireless powering to eliminate the need for implanted batteries, significantly reducing device size and improving patient comfort compared to traditional neuromodulation systems.

Differentiator

Problem solved

Functional benefit

Brands

  • Nuvella: First-generation sacral neuromodulation system name used during clinical trials; later branded as iSNM system
  • iSNM System
  • pSNM System

Products and services

  • Neuspera Integrated Sacral Neuromodulation (iSNM) System FDA-approved integrated sacral neuromodulation system for urinary urge incontinence (UUI) consisting of an ultra-miniaturized neurostimulator implant (100x smaller than traditional devices), an external battery/therapy disc worn against the lower back, a smartphone application for therapy adjustments, and an iPad-based clinician programmer. Eliminates the need for implanted batteries while delivering gold-standard SNM efficacy. Designed for urologists and urogynecologists treating UUI patients who have failed medication management.
  • Neuspera Peripheral Nerve Stimulation (PNS) System FDA-cleared first-of-its-kind leadless micro-implant system for chronic peripheral nerve pain management. 75x smaller than the smallest commercial implantable pulse generator, featuring a wireless platform with wearable transmitter and iPad-based clinician programmer. Designed for pain management physicians and specialists treating chronic peripheral nerve pain.

Quantifiable outcome

  • 84.2% of implanted patients achieved at least 50% reduction in urgent leaks at 6 months (Phase II pivotal trial, 128 patients)
  • +9 more outcomes

Companies that use NeuSpera Medical

Customer profile

Named customers6 records

Segments2 records

Ideal customer profiles2 records

NeuSpera Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

NeuSpera Medical partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • MedTech InnovatorminorStrategic or Co-development Partner · 3 June 2024Neuspera was selected as one of 65 startups in the 2024 MedTech Innovator Cohort, providing visibility within the medtech ecosystem and access to mentorship, networking, and potential partnership opportunities with larger medtech companies.
  • AdvaMedminorOthersNeuspera Medical is a member of AdvaMed (Advanced Medical Technology Association), the leading trade association for the medical technology industry. The company and its employees follow applicable laws and regulations for the medical device industry.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

NeuSpera Medical competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Medtronic is the incumbent market leader in sacral neuromodulation through its InterStim system, which has dominated the UUI/OAB market since 1997. Medtronic is Neuspera's primary direct competitor and the entrenched incumbent Neuspera must displace, with deep physician relationships and a multi-decade head start in SNM.
  • Boston Scientific: Boston Scientific is a broad incumbent in neuromodulation (spinal cord stimulation, deep brain stimulation, dorsal root ganglion) and acquired Axonics in 2024 to enter the SNM market. Courtney Lane, Neuspera's VP of Clinical, Quality and Regulatory, previously led clinical affairs at Axonics and worked on Boston Scientific's DBS program.
  • Abbott: Abbott is a broad neuromodulation incumbent with the Proclaim DRG system for dorsal root ganglion stimulation and other neurostimulation products. As a large diversified medical device company with extensive salesforce coverage, Abbott represents both a competitive threat and potential strategic acquirer for smaller neuromodulation players.
  • Coloplast: Coloplast is a major urology medical device company offering continence care products and interventional urology solutions. Neuspera's former CEO Steffen Hovard previously led Coloplast Interventional Urology, and Coloplast competes broadly in the urology space where Neuspera is launching its iSNM system.

Direct peers

  • Axonics Modulation Technologies: Axonics is Neuspera's most direct competitor, offering rechargeable sacral neuromodulation and peripheral nerve stimulation systems. Axonics was acquired by Boston Scientific, giving it the resources and salesforce to compete aggressively against Neuspera's battery-free iSNM system.
  • Nevro: Nevro develops the Senza spinal cord stimulation system for chronic pain, competing in the neuromodulation space with Neuspera's PNS system. Both companies target the chronic pain market with neurostimulation devices, though Nevro focuses on spinal cord while Neuspera targets peripheral nerves.

Emerging players

  • Inspire Medical Systems: Inspire Medical Systems is an emerging neuromodulation company with an FDA-approved hypoglossal nerve stimulation system for obstructive sleep apnea. Inspire represents a successful case study of a focused neuromodulation company scaling to commercial success, with a comparable sales motion to urology/specialty physician segments.
  • Saluda Medical: Saluda Medical is an emerging neuromodulation company with the Evoke spinal cord stimulation system featuring closed-loop sensing technology. Saluda represents a next-generation neuromodulation competitor with innovative technology approaches similar to Neuspera's proprietary mid-field powering platform.
  • SPR Therapeutics: SPR Therapeutics develops peripheral nerve stimulation systems for pain management, directly competing with Neuspera's FDA-cleared PNS system. SPR focuses on minimally-invasive PNS for acute and chronic pain, representing an emerging competitor in Neuspera's PNS indication.
  • Nalu Medical: Nalu Medical develops a miniature peripheral nerve stimulation system for chronic pain, competing with Neuspera's PNS platform. Nalu's ultra-small implant and wearable battery form factor parallels Neuspera's miniaturization approach, making it a comparable emerging player in PNS.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

NeuSpera Medical social profiles

Digital presence

NeuSpera Medical compliance and trust

Trust signal

Compliance2 records

NeuSpera Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeuSpera Medical leadership team

Management profile

Number of profiles

Profiles9 records

NeuSpera Medical funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeuSpera Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuSpera Medical

What does NeuSpera Medical do?

NeuSpera Medical designs, manufactures, and sells ultra-miniaturized implantable neuromodulation medical devices powered by its proprietary Mid-Field Powering Technology. The company's flagship product is the FDA-approved Integrated Sacral Neuromodulation (iSNM) system for urinary urge incontinence, which consists of an ultra-miniaturized implant, an external battery disc, a smartphone app, and an iPad-based clinician programmer. The company also offers an FDA-cleared Peripheral Nerve Stimulation (PNS) system for chronic nerve pain, and external wearable components that represent recurring accessory revenue.

Is NeuSpera Medical a public or private company?

NeuSpera Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was NeuSpera Medical founded?

NeuSpera Medical was founded in 2014. It employs 11 to 50 people.

Where is NeuSpera Medical based?

NeuSpera Medical is headquartered in San Jose, United States, in the North America region.

How does NeuSpera Medical make money?

Two revenue lines are on record. Implantable Medical Device Sales are the primary driver. The others are external Therapy Disc / Wearable Component Sales.

Who are NeuSpera Medical's main competitors?

Broad incumbents on record are Medtronic, Boston Scientific, Abbott and Coloplast. Direct peers are Axonics Modulation Technologies and Nevro. Emerging players are Inspire Medical Systems, Saluda Medical, SPR Therapeutics and Nalu Medical.

Does NeuSpera Medical have an API?

No public API is recorded for NeuSpera Medical.

What industry is NeuSpera Medical in?

NeuSpera Medical's product category is Implantable Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAKAIAM, Pain Medicine (Interventional/Neuropathic Pain). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Urology TimesPivotal study data show efficacy of percutaneous SNM device for UUINeuspera Medical reported that its percutaneous sacral neuromodulation (pSNM) device demonstrated promising efficacy in managing urge urinary incontinence, with 84.2% of patients achieving a significant reduction in symptoms during the phase 2 SANS UUI trial. The company submitted an application for premarket approval to the FDA in September 2024 and anticipates a decision later this year.Urology TimesTrial progresses of SNM device for urge urinary incontinenceNeuspera Medical announced that all patients have completed the primary endpoint visit for Phase 2 of the SANS-UUI trial, which evaluates its Implantable Sacral Neuromodulation System for urge urinary incontinence. The company plans to use data from this trial to support an application to the FDA for approval of the device for this indication. Final completion of the trial is expected in December 2026.Urology TimesFDA approves integrated sacral neuromodulation system for urinary urge incontinenceThe FDA has granted clearance to Neuspera Medical’s integrated sacral neuromodulation (iSNM) system for the treatment of urinary urge incontinence. This approval is supported by pivotal phase 2 trial results showing that 84.2% of patients achieved at least a 50% reduction in urgent leaks, offering a battery-free alternative to traditional implants.Urology TimesExpert outlines advantages of batteryless sacral neuromodulation deviceNeuspera Medical presented six-month clinical trial data for its battery-free percutaneous sacral neuromodulation device, showing that 84.2% of patients achieved a 50% or greater reduction in urgent leaks. The device offers advantages such as a smaller size and simplified implantation procedure due to the absence of a generator, appealing to active patients and those concerned with cosmesis. An expert noted that while the treatment simplifies the procedure for clinicians, it may not suit patients preferring a 'set it and forget it' approach.Urology TimesAndrea Pezzella, MD, URPS, FACOG, discusses Neuspera's integrated sacral neuromodulation systemThe FDA granted clearance to Neuspera Medical’s integrated sacral neuromodulation (iSNM) system for treating urinary urge incontinence on June 18, 2025. The device is highlighted as a battery-free alternative to traditional implanted systems, addressing clinical burdens associated with battery replacements and revisions.MassDeviceNeuspera earns Medicare win for sacral neuromodThe Centers for Medicare & Medicaid Services (CMS) confirmed billing code assignment for Neuspera Medical's SNM system, placing it in payment level APC 5464 in the proposed CY 2027 Outpatient Prospective Payment System Rule. The decision grants Neuspera's externally powered integrated SNM system equivalent Medicare payment to all other implantable neuromodulation therapies for urinary urge incontinence, with the rate increasing to $22,150 for CY 2027—an 11.8% increase from 2026. Neuspera holds FDA approval for the UUI treatment and received FDA clearance in 2024 for chronic pain of peripheral nerve origin, positioning the externally powered system as an alternative to fully implantable options from competitors.PR NewswireNeuspera Integrated Sacral Neuromodulation System (iSNM) to Receive Same Medicare Payment as Legacy Implantable SNM Devices Under Proposed 2027 CMS RuleThe Centers for Medicare & Medicaid Services (CMS) has proposed assigning Neuspera Medical's Sacral Neuromodulation System to payment level APC 5464 in the CY 2027 Outpatient Prospective Payment System Rule, granting the externally powered iSNM system reimbursement parity with legacy implantable SNM devices. The proposed payment rate for APC 5464 is $22,150, an 11.8% increase from 2026, and combined with the prior addition of the billing code to Medicare's National Coverage Determination 230.18, this provides broad access for Medicare beneficiaries to Neuspera's technology. Neuspera's FDA-approved iSNM system eliminates drawbacks of traditional battery-powered SNM systems from Boston Scientific and Medtronic, which collectively serve the $1 billion legacy sacral neuromodulation market.Medical Device NetworkNeuspera reports positive data in urinary urge incontinence device trialNeuspera Medical reported positive 12-month pivotal trial results for its Neuspera SNM system, an integrated sacral neuromodulation device for urinary urge incontinence, with 94% of test-phase responders experiencing at least a 50% decrease in UUI episodes and 81% classified as super-responders with 75%+ reduction. The device demonstrated an excellent safety profile with zero serious device-related adverse events and zero infections over 12 months, while also showing potential for reduced therapy with 30 minutes of daily treatment. The FDA approved Neuspera Medical's iSNM system for treating UUI in June 2025, with clinical investigators participating from the US and Europe.PR NewswireNeuspera Medical Announces 12-Month Pivotal Trial Results for the Company's Integrated Sacral Neuromodulation System for Urinary Urge IncontinenceNeuspera Medical announced positive 12-month pivotal trial results for the Neuspera SNM System, an integrated sacral neuromodulation device for urinary urge incontinence, with 94% of test-phase responders achieving at least 50% reduction in urgent urinary incontinence episodes, 81% classified as super-responders with at least 75% reduction, and 43% completely dry with 100% reduction. The system maintained an excellent safety profile with zero serious device-related adverse events and zero infections through 12 months. The company, which received FDA approval for the device in June 2025, presented the data at the SUFU Winter Meeting and announced plans to present additional data on reduced therapy durations at the AUA Annual Meeting later this year.